Dupilumab showed rapid improvement in itch in patients with moderate to severe atopic dermatitis, according to an analysis of four phase 3 trials. The analysis included 1,505 patients with AD, of which 251 were adolescents, in four randomized controlled studies: SOLO 1, SOLO 2, AD ADOL and CHRONOS. Adults in the studies received 300 mg of dupilumab every 2 weeks or placebo monotherapy, with concomitant topical corticosteroids. Adolescents between 12 and 18 years of age received dupilumab monotherapy of either 200 mg (patients under 60 kg) or 300 mg (patients over 60 kg) every 2 weeks or placebo.

 

Read more…